Liver Cancer News 2018

Blue Faery



Liver Cancer News 2018

Print Friendly, PDF & Email

Can DNA Methylation Help Us Understand And Diagnose Cancer Better?
28 March 2018
Paul Ehrlich, of the late 19th century, proposed that the immune system plays a vital role in preventing cancer development. Researchers recently conducted a study to determine if DNA methylation can be used to diagnose cancer. They investigated if immune cells within peripheral blood change their epigenetics as cancer progresses in Hepatocellular Carcinoma (HCC). Researchers examined the DNA methylation pattern in patient blood samples; they found that methylation was correlated with the progression of HCC.

Exelixis’ Partner Ipsen Announces EMA Validation Of The Application For A New Indication For CABOMETYX® (Cabozantinib) For Previously Treated Advanced Hepatocellular Carcinoma
28 March 2018
Ipsen received validation of the application for variation to the CABOMETYX® (cabozantinib) for the addition of a new indication for patients with previously treated advanced Hepatocellular Carcinoma (HCC). This came based on results of the phase 3 CELESTIAL trial, which met its primary endpoint of overall survival, with cabozantinib providing a statistically significant and clinically meaningful improvement in overall survival, compared with placebo in patients with advanced HCC who had been previously treated with sorafenib

Obesity Increases Risk For Hepatocellular Carcinoma With Hepatitis B Infection
22 March 2018
Researchers have shown that men and women with high BMI and hepatitis B virus infection are at increased risk for Hepatocellular Carcinoma. A group of patients were followed from January 2007 to December 2015 and excised at first incidence of HCC. Patients were grouped based on BMI. The association between BMI and HCC appeared greater among overweight women than overweight men.

New Anti-Cancer Protein Discovered
21 March 2018
Researchers have discovered a new anti-cancer protein called histidine phosphatase (LHPP). This protein prevents the uncontrolled proliferation of cancer cells in the liver. The number of cases has almost doubled in Switzerland in the last 20 years. Leading the researcher is Prof. Michael N. Hall from the Biozentrum, University of Basel who reports that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer. LHPP is present in healthy tissue and completely absent in tumor tissue.

Cuba To Study Vaccine Candidate Against Hepatocelluar Carcinoma
19 Mar 2018
Cuba hopes to introduce a prevention strategy for HCC that involves the diagnosis of Hepatitis C in blood donors in order to decrease the transmission. A new clinical trial has been approved by the Regulatory Authority for Medicines, Equipment and Medical Devices of the Republic of Cuba. Scientists will test the efficacy of the vaccine Hebersavax, to be used for the treatment of patients with Hepatocellular Carcinoma. This trial will take place at Cimeq, a certified good health institution. Dr. Francisco Hernández Bernal, professor and principal investigator of the CIGB and clinical manager of the project, explained that it is the first study in humans with this vaccine.

TACE-RT Ups Survival In Advanced HCC: Combination Tops Sorafenib Alone
18 March 2018
Hepatocellular Carcinoma (HCC) patients with vascular invasion lived longer when treated with a combination of transarterial chemoembolization plus external-beam radiotherapy (TACE-RT) than with sorafenib (Nexavar). In a study of 90 HCC patients with macroscopic portal vein invasion, the median overall survival among those treated with TACE-RT was 55 weeks versus 43 weeks in those treated with sorafenib alone. The results of this trial were presented at the 2018 Gastrointestinal Cancers Symposium along with positive data for TACE plus sorafenib versus TACE alone.

The Role Of Dermcidin In The Diagnosis And Staging Of Hepatocellular Carcinoma
16 Mar 2018
In this study, scientists measured serum DCD and alpha-fetoprotein (AFP) levels in 87 HCC patients and evaluated the relationship between DCD levels and clinicopathological parameters. In this prospective study, blood samples were collected from HCC, liver cirrhosis (LC) without HCC, and noncirrhotic non-HCC patients treated at Guangzhou Hospital of Traditional Chinese Medicine from October 2014 to May 2015. Alpha-fetoprotein (AFP), a plasma protein produced by the yolk sac and fetal liver cells. AFP is the most widely used biomarker for HCC. It is important to identify novel serum biomarkers with high diagnostic accuracy to detect HCC and its metastasis.

Eisai And Merck & Co. Enter Global Strategic Oncology Collaboration For LENVIMA
8 March 2018
An announcement was made that the companies have agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai. Per the agreement, the companies will also jointly initiate new clinical studies evaluating the LENVIMA/KEYTRUDA combination to support 11 potential indications in six types of cancer (endometrial cancer, non-small cell lung cancer, Hepatocellular Carcinoma, head and neck cancer, bladder cancer and melanoma), as well as a basket trial targeting multiple cancer types. Phase 1b clinical study (Study 116/KEYNOTE-524) of LENVIMA in combination with KEYTRUDA in Hepatocellular Carcinoma being conducted in Japan and the United States.

BMS’ Opdivo Cleared For Monthly Use
7 March 2018
US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every four weeks. The company says the approval will allow physicians to customize patient care with the option of using the newly approved dose of 480mg every four weeks. “With this approval, we now offer the most robust range of dosing options for an Immuno-Oncology medicine, providing enhanced flexibility to help address each patient’s specific needs,” said Johanna Mercier, head, US Commercial, BMS.

Radioembolization Shows Similar OS, Improved Toxicity Vs Sorafenib In Hepatocellular Carcinoma
5 March 2018
Selective internal radiation therapy/radioembolization (RE) and sorafenib yield similar overall survival (OS) outcomes among patients with unresectable Hepatocellular Carcinoma (HCC). Radioembolization may, however, have a superior toxicity profile. Researchers randomly assigned 360 patients with locally advanced HCC to receive RE with yttrium-90 (90Y) resin microspheres or sorafenib 800 mg daily. Patients were enrolled regardless of portal vein thrombosis status and were unable to tolerate other curative therapies.

Cancer Stem Cells, Allies Of The Tumor And Enemies Of The Patient
5 March 2018
The scientists of the UEx Molecular Biology of Cancer Research Group want to uncover the physiological mechanisms of the cancer stem cell, the archenemy of the patient because it is responsible for the progression of the tumor. One specific protein might contribute to keeping the tumor in a more highly undifferentiated state that could affect its metastatic capacity and its response to therapy. Researchers have already observed how a certain cell protein, the dioxin receptor (Ahr), participates in this process of cellular differentiation. This investigation is part of the project “Role of dioxin receptor in pluripotency and reprogramming: novel mechanisms regulating tumor cell differentiation.”

Hepatitis C Virus And Hepatocellular Carcinoma: Pathogenetic Mechanisms And Impact Of Direct-Acting Antivirals
3 March 2018
Globally, between 64 and 103 million people are chronically infected with Hepatitis C virus (HCV), with more than 4.6 million people in the United States and is associated with more than 15.000 deaths annually. Chronic infection can result in cirrhosis and Hepatocellular Carcinoma. In the developing world, viral hepatitis (primarily hepatitis B) continues to represent a major risk for the development of HCC. Worldwide, chronic HBV infection accounts for approximately 50% of all cases of Hepatocellular Carcinoma and virtually all childhood cases.

Liver Cancer: A New Method For Identifying Splicing Biomarkers Developed
3 March 2018
Researchers have developed a method for identifying splicing-based biomarkers for the most common form of liver cancer, Hepatocellular Carcinoma (HCC). The team tested their splicing-variant detection method in HCC, by analyzing RNA messages in HCC cells sampled from hundreds of patients. Fixing AFMID splicing could lead to an increase in DNA repair.

New Method Identifies Splicing Biomarkers For Liver Cancer
2 March 2018
Researchers at Cold Spring Harbor Laboratory (CSHL), led by CSHL Professor Adrian Krainer, now report in Genome Research that they have developed a method for identifying splicing-based biomarkers for the most common form of liver cancer, Hepatocellular Carcinoma. Splicing refers to a process in which an RNA message copied from information encoded in a gene is edited before it is able to serve as a blueprint for the manufacture of a specific protein. “If we can do this, AFMID splicing can become a therapeutic target and the source of a new drug for liver cancer,” said researcher Kuan-Ting Lin.

Mapping A Functional Cancer Genome Atlas Of Tumor Suppressors In Mouse Liver Using AAV-CRISPR–Mediated Direct In Vivo Screening
28 Feb 2018
Large-scale molecular profiling of patient samples has tremendously improved our understanding of human cancers. Given that AAVs can efficiently infect the liver after intravenous injection, the team reasoned that liver Hepatocellular Carcinoma would be a suitable and relevant model. The data indicates that AAV-CRISPR mTSG directly promotes aggressive liver tumorigenesis.

Lab-Grown Liver Tumors Help Singapore Scientists To Develop Anti-Cancer Drugs
28 February 2018
A team of scientists has managed to grow tiny liver cancer tumors in a laboratory, which they believe could hold the key to treating one of Singapore’s deadliest diseases. Anti-cancer drugs can be tested on them, allowing scientists to see how effective they are within a week or so.

AEOI Experts Produce New Radio-Drug
25 February 2018
Researchers at the Atomic Energy Organization of Iran (AEOI) have produced a new radiopharmaceutical for treatment of liver cancer. The new radiopharmaceutical is named Y-90 Resin Microspheres, which is used in treatment of metastatic liver cancer, as well as Hepatocellular Carcinoma (HCC), the most common type of primary liver cancer.

Mini Tumor Models Offer New Insights Into Liver Cancer
23 February 2018
Scientists have used laboratory models of tumors to identify a new drug that could be a potential liver cancer treatment. Experts from the Wellcome/Cancer Research UK Gurdon Institute in Cambridge created mini biological models of human primary liver cancers, known as organoids.

New AASLD Guidelines For Hepatocellular Carcinoma: The Big Questions Tackled
21 February 2018
Hello. I’m Dr. David Johnson, professor of medicine and chief of gastroenterology at Eastern Virginia Medical School in Norfolk, Virginia. When we see patients with cirrhosis in the clinic, we are concerned about screening for Hepatocellular Carcinoma (HCC). I’m not a transplant hepatologist, but I deal with these patients all the time, as you do. HCC is an incredibly common disease.

Cabometyx™ May Be ‘New Treatment Option’ For Liver Cancer
20 February 2018
Treatment with Cabometyx (cabozantinib) significantly improved outcomes in patients with advanced Hepatocellular Carcinoma (HCC); leading researchers to suggest that it could offer a new treatment option for this patient population.  The new findings come from the phase 3 CELESTIAL trial and were presented at the 2018 Gastrointestinal Cancers Symposium.

Perthera Inc. And Blue Faery Announce Their Partnership Against Liver Cancer
20 February 2018
Perthera, Inc., the leading Therapeutics Intelligence Company™, has announced its partnership with Blue Faery, the leading Hepatocellular Carcinoma advocacy group in the US, with the goal to provide liver cancer patients with therapeutic treatment options precisely matched to their individual cancers.

Lenvatinib HCC Data Published As FDA Considers Approval
20 February 2018
Lenvatinib (Lenvima) was noninferior for overall survival (OS) while improving progression-free survival (PFS) compared with sorafenib (Nexavar) for the frontline treatment of patients with unresectable Hepatocellular Carcinoma (HCC), according to findings from the phase III REFLECT trial now published online in the Lancet.

Keytruda Immunotherapy Appears Active For Treatment Of Liver Cancer
15 February 2018
According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib). Liver cancer, or Hepatocellular Carcinoma (HCC), is the second most common cause of cancer-related deaths worldwide. The prognosis for patients with advanced liver cancer is poor, and the multikinase inhibitor, Nexavar, has been the only approved treatment, until the recent approval of Stirvaga.3

Multiple Factors To Consider Before Choosing Treatment For Liver Cancer
15 February 2018
DEAR MAYO CLINIC: Is removing part of the liver always the best treatment for liver cancer? What if the cancer has spread?
ANSWER: Surgery to remove part of the liver sometimes can be a successful treatment for liver cancer, but that’s not always the case. A variety of other options also are available to treat liver cancer. How much the cancer has spread, along with a person’s age and overall health, helps determine the best treatment choice.

New Direction In Treatment Of Cancer
14 February 2018
An expert expects that in 10 years there will be a cure for cancer. Speaking to The Independent newspaper ahead of the World Cancer Day on 4 February 2017, Prof. Karol Sikora, who is a former head of the World Health Organisation’s cancer programme, said that advancement in genetics meant that doctors would be able to prescribe drugs targeted explicitly at cancer.

Biotech With Tenbagger Potential Signs Deal With Chinese Firm
14 February 2018
In a Feb. 12 research report, Pantginis noted that Rexahn Pharmaceuticals Inc. entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology Co. to develop its Akt-1 inhibitor, Archexin (RX-0201), as a Hepatocellular Carcinoma therapy (HCC). “We view this transaction positively,” said Pantginis. “Overall, we are impressed with the terms that Rexahn achieved for a new formulation and indication that has not even gotten off the ground yet.”

Vaccines That Can Prevent Cancers
13 February 2018
The viruses that are associated with cancers include hepatitis B and C viruses (HBV and HCV), human papilloma viruses (HPV), human T-cell leukemia virus (HTLV-1), human immunodeficiency virus (HIV), Epstein-Barr virus (EBV), human herpes virus 8 (HHV-8) which is also known as Kaposi sarcoma-associated herpes virus (KSHV), and Merkel cell polyomavirus (MCV). The hepatitis B and C viruses can give rise to chronic hepatitis B and C, respectively, conditions that lead to cirrhosis or severe scarring of the liver, which in turn predisposes one to liver cancer.

Type Of Health Insurance And Marital Status Affect Outcomes In Liver Cancer
12 February 2018
People treated for liver cancer at an inner-city hospital experienced better survival odds if they had private health insurance, and if they were married, according to the results of a recent study that considered how socioeconomic factors affect health outcomes for those with the disease.

Celsion Announces Thermodox® HEAT Study Presentation At Korean Liver Cancer Association’s 12th Annual Scientific Meeting
12 February 2018
Celsion Corporation today announced that an abstract discussing the Company’s Phase III HEAT study evaluating ThermoDox® in combination with radiofrequency ablation (RFA) was one of six selected for presentation as part of the lecture of the Presidential Selection at the Korean Liver Cancer Association’s 12th Annual Scientific Meeting in Seoul, South Korea.

Ethnic Disparities Evaporate With DAA Treatment Of Hepatitis C Infections
12 February 2018
Early diagnosis and treatment of hepatitis C virus (HCV) infections can prevent liver cancer and end-stage liver disease even in high-risk ethnic minorities, according to a new study. There is a well-known ethnic disparity in the U.S. among HCV patients, with a higher risk of cancer, cirrhosis and long-term outcomes among Hispanic and Asian patients as compared to Caucasians. In the interferon era, studies showed Asians had the lowest rate of treatment, and African Americans and Hispanics were less likely to receive care than Caucasians.

Simple Tips To Keep Your Liver Healthy
11 February 2018
Everything we do and take in somehow affects our liver. Our liver performs over 500 functions that work to keep us healthy overall. But what do we do when the liver gets sick? Your best defense against a sick liver is to adhere to a healthy lifestyle as much as possible. It’s really that simple. Here are some easy to do tips that can promote a healthy liver.

Calling Out A ‘Silent Killer’
11 February 2018
Driving my boyfriend home from chemotherapy, we couldn’t believe the ad on the bus in the next lane. We had to read it again at a red light. The ad warned that one in 10 Asian Americans are infected with hepatitis B and don’t know it — with a quarter of hepatitis B carriers at risk of dying from liver cancer or failure. Nothing about my boyfriend’s illness made sense until we saw that ad … At 30, Mark Lim was diagnosed with inoperable liver cancer caused by hepatitis B.

Liver Cancer And Treatment
10 February 2018
Liver cancer is one of the commonest causes of cancer related deaths in the world. The cancer may originate from the liver itself called Hepatocellular cancer (HCC) or may be a result of spread from other organs (Metastatic cancer). The HCC usually develops in an already diseased liver (shrunken liver called cirrhosis). The cirrhosis in turn may be a result of longstanding infection (hepatitis B, hepatitis C etc.), Alcohol consumption, fatty liver disease, congenital liver diseases and so on.

‘But I Persisted’: Angelina Lay Didn’t Start School Until 12 But Now She’s A Doctor Helping To Cure Liver Cancer
10 February 2018
In an unassuming laboratory in Sydney, a scientist is shining a light on cirrhosis and liver cancer — the cancer killing Australians at the fastest growing rate. Dr. Angelina Lay is a well-published scientist who is proud that she’s helping advance treatments for liver disease, but that she even got through school is something of a miracle.

Recreating Liver Tumors As Organoids For Faster, More Accurate Drug Screening
9 February 2018
Liver cancer is one of the top causes of cancer deaths globally, with a lack of approved treatments. A major challenge in developing effective drugs for liver cancer is that current preclinical tumor models do not accurately replicate features of the tumor and the tumor environment in humans, causing many potential drugs to fail in clinical testing.

Study Shows Liver Cells With Whole Genome Duplications Protect Against Cancer
9 February 2018
Researchers at the Children’s Medical Center Research Institute (CRI) at UT Southwestern have discovered that cells in the liver with whole genome duplications, known as polyploid cells, can protect the liver against cancer. The study, published online today in Developmental Cell, addresses a long-standing mystery in liver biology and could stimulate new ideas to prevent cancer.

Liver Cancer Patients Barred From NHS Access To Bayer’s Stivarga
9 February 2018
It is now looking very unlikely that patients with liver cancer will get access to Bayer’s Stivarga on the NHS, after cost regulators issued final draft guidelines rejecting funding for the drug in this setting. The National Institute for Health and Care Excellence is sticking with its decision not to recommend the drug’s use to treat liver cancer that has spread around the body, is inoperable and has previously been treated with the drug, sorafenib.

Superior Court Judge Ola Lewis Says Cancer Treatments Are Working
9 February 2018
Senior Superior Court Judge Ola Lewis said Friday morning that treatments for her liver cancer are working. “The cancer is shrinking,” Lewis said. “Round 4 of chemo next week! Cancer numbers went from 202 to 37! Praise God!”

Blood Test Plus Ultrasound Boosts Liver Cancer Detection By 40 Percent
8 February 2018
Combining ultrasound imaging with a blood test for high alpha-fetoprotein (AFP) levels improves detection of early-stage liver cancer by as much as 40 percent, researchers at UT Southwestern’s Simmons Cancer Center found. Earlier detection is important to improving survival of patients with liver cancer, a disease that is on the rise and the fastest increasing solid-tumor cancer in the U.S., according to the National Cancer Institute (NCI).

Rexahn Pharmaceuticals Announces Collaboration With Zhejiang Haichang Biotechnology Co., Ltd. For The Development Of RX-0201 (Archexin®) For The Treatment Of Hepatocellular Carcinoma
8 February 2018
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology Co., Ltd. (Haichang), to develop RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma (HCC), the most common form of liver cancer.

IILDS And Medgenome Inaugurate R&D Centre At Sonarpur
7 February 2018
Indian Institute of Liver and Digestive Sciences, a brainchild of The Liver Foundation, West Bengal, in association with MedGenome, announced the launch of the R&D centre at IILDS, Sonarpur. The centre would provide a deeper understanding of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Indian subcontinent. NAFLD is the most common liver ailments that can lead to cirrhosis and Hepatocellular Carcinoma.

Burbank’s Mayor Going Strong Despite Cancer Diagnosis
5 February 2018
Last month, the Burbank City Council held its first public session of the new year. Normally, this wouldn’t really be a big deal. Lots of city councils are getting back to work after the winter break.

Liver Cancer Symptoms — Seven Signs Of The DEADLY Condition
5 February 2018
Liver cancer is a rare condition that’s linked to damage and scarring of the liver, known as cirrhosis. Several types of cancer can form in the liver, but Hepatocellular Carcinoma is the most common type. Signs and symptoms of the disease are difficult to spot to begin with, said the NHS. “Symptoms of liver cancer are often vague and don’t appear until the cancer is at an advanced stage,” it said.

Liver Cancer Deaths Up 80% Since 1990, Hepatitis B And C Mostly To Blame: 5 Insights
2 February 2018
Deaths from liver cancer increased by 80 percent in the last two decades, making liver cancer the second leading cause of cancer deaths worldwide after lung cancer. Here are five things to know: In 2016, 830,000 people died as a result of the disease compared to 464,000 people in 1990, according to the Global Burden of Disease Study, the most comprehensive worldwide epidemiological observational study to date.

Detection Kit Shows Promise In Liver Cancer Patients
2 February 2018
Liver cancer is one of the world’s deadliest cancers. And, it’s particularly common in China.  Now, new technology could bring hope to patients.

Dr. Abou-Alfa On Sequencing Agents In The Treatment Of Patients With HCC
2 February 2018
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of cabozantinib (Cabometyx) in Hepatocellular Carcinoma (HCC) could affect the treatment landscape in liver cancer.

Researchers Discover Two-Step Process To Thwart Cancer Cells
2 February 2018
Scientists at the University of Delaware and the University of Illinois at Chicago have found a new way to kill liver cancer cells and inhibit tumor growth. First, they silence a key cellular enzyme, and then they add a powerful drug. They describe their methods in a new paper published in Nature Communications.

Healthcast: A Study On Deaths From Liver Cancer
1 February 2018
A new study found deaths from liver cancer have increased by 80% since the 1990’s, making it one of the fastest-growing causes of cancer deaths worldwide, second to lung cancer. Primary liver cancer can be attributed to heavy drinking as well as long-term infections with the hepatitis B or C virus.

5 Things You Can Do To Improve Your Liver
1 February 2018
As many people are attempting new diets in the new year, some are turning to detox diets to “cleanse their liver.” Maybe it’s the idea we’re poisoning ourselves with toxic foods that drive some to seek out a liver detox diet. But there are far easier steps you can take to prevent liver disease. A liver detox diet is not one of them.

UT Southwestern Oncologist Highlights Need To Improve Liver Cancer Screening Rates
30 January 2018
Patients with cirrhosis should be screened regularly for liver cancer, though few are – in part, because busy physicians often don’t order the screening tests, said UT Southwestern oncologists. “The frequency of liver cancer is increasing rapidly in the U.S. and liver cancer-related mortality has nearly doubled over the past decade. The poor prognosis of the disease is largely driven by the failure to diagnose the disease at an early stage,” said Dr. Amit G. Singal, Medical Director of the Liver Tumor Program at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center.

Marijuana Could Help Protect Alcoholics From Liver Damage
30 January 2018
“Our study revealed that among alcohol users, individuals who additionally use cannabis (dependent and non-dependent cannabis use) showed significantly lower odds of developing alcoholic steatosis (AS), steatohepatitis (AH), cirrhosis (AC) and Hepatocellular Carcinoma (HCC),” the study reads, according to BGR.

Exelixis: Cabozantinib Shows Better Efficacy Profile Than Competition
30 January 2018
It is approved for advanced renal cell carcinoma, metastatic thyroid cancer and is undergoing trials for Hepatocellular Carcinoma. Recently, Exelixis and partner Ipsen reported strong results for cabozantinib in Hepatocellular Carcinoma (HCC), a new indication, bringing the fight even closer to the likes of sorafenib (Nexavar).

Dr. Zhu Discusses Findings Of The KEYNOTE-224 In HCC
29 January 2018
Andrew Zhu, MD, PhD, directory, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the findings of KEYNOTE-224 in Hepatocellular Carcinoma (HCC). KEYNOTE-224 evaluated pembrolizumab (Keytruda) in patients with advanced HCC who had been previously treated with sorafenib (Nexavar).

2018 Gastrointestinal Cancers Symposium Highlights
29 January 2018
In Hepatocellular Carcinoma, phase III findings of the CELESTIAL trial presented during the meeting showed that treatment with cabozantinib improved median overall survival by 2.2 months versus placebo for patients with previously treated advanced disease.

Small-For-Size Graft In Liver Transplantation Outside Milan Criteria Presents Worse Outcomes
29 January 2018
Patients who received small-for-size grafts during liver transplantation for Hepatocellular Carcinoma outside Milan criteria had worse rates of recurrence and survival compared with patients within Milan criteria, according to a recently published study.

New AASLD Guideline Focuses On Improving Diagnosis, Treatment Of Liver Cancer And NAFLD
27 January 2018
A new Practice Guideline and Practice Guidance in Hepatology will help improve the diagnosis and treatment of patients with liver cancer as well as patients with non-alcoholic fatty liver disease (NAFLD), which can lead to liver cancer and is characterized by the build-up of extra fat in liver cells often due to obesity and diabetes.

Losing Your Parents When You Know Nothing Of Death: Solace And Sorrow In The Dead Parent’s Society
26 January 2018
A doctor would run a pen along each line of Mum’s oncologist report, in a few months’ time, pausing to translate the jargon. Primary Hepatocellular Carcinoma (liver cancer) and invasive ductal carcinoma (breast cancer) had resulted in metastatic intraspinal extradural tumors (spinal cancer).

Pembrolizumab Elicits Promising Activity In HCC Patients Previously Treated With Sorafenib
25 January 2018
In phase II data reported at the 2018 Gastrointestinal Cancers Symposium, treatment with the PD-1 inhibitor pembrolizumab (Keytruda) elicited promising progression-free survival (PFS) and overall survival (OS) results in patients with advanced Hepatocellular Carcinoma (HCC) who received previous treatment with sorafenib.

Liver Cancer – Identifying And Commercializing First-In-Class Innovation Market Report
25 January 2018
Globally, liver cancer is the sixth most common cancer, but its poor prognosis makes it the second leading cause of cancer-related death (Globocan, 2012). Currently, the range of therapies is limited; the market consisted entirely of chemotherapies for many years, and only recently have targeted therapies begun to emerge.

Radiofrequency Ablation Improves Survival Over SBRT In Localized HCC
24 January 2018
Radiofrequency ablation (RFA) was associated with superior five-year overall survival (OS) compared with stereotactic body radiotherapy (SBRT) for patients with localized Hepatocellular Carcinoma, according to an observational study published in the Journal of Clinical Oncology.

Merck Reports Positive Phase III Liver Cancer Data On Keytruda
22 January 2018
Merck & Co., Inc. announced data from the phase II KEYNOTE-224 study evaluating the use of its anti-PD-1 therapy, Keytruda in patients with advanced Hepatocellular Carcinoma (HCC), a form of liver cancer, who were previously treated with systemic therapy (sorafenib). The data showed that treatment with Keytruda monotherapy led to an overall response rate (ORR) of 16.3%.

Hepatocellular Carcinoma HCC Treatment Market To Receive Overwhelming Hike In Revenues
22 January 2018
Hepatocellular Carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon Hepatocellular Carcinoma is anticipated to witness rise in incidence rate during the forecast period. HCC is currently expected to be the third leading cause of death worldwide.

Adolescent Drinking Can Cause Liver Problems Later In Life
21 January 2018
Data indicated that alcohol consumption early in life was associated with an increased risk of developing severe liver disease. After 39 years of follow-up, 383 men had developed severe liver disease, which was defined as a diagnosis of liver cirrhosis, decompensated liver disease (Hepatocellular Carcinoma, ascites, esophageal varices, hepatorenal syndrome, or hepatic encephalopathy), liver failure, or death from liver disease.

Study: Marijuana Use Associated With Reduced Prevalence Of Liver Disease In Alcoholics
20 January 2018
“Abusive alcohol use has well-established health risks including causing liver disease (ALD) characterized by alcoholic steatosis (AS), steatohepatitis (AH), fibrosis, cirrhosis (AC) and Hepatocellular Carcinoma (HCC)”, states the study’s abstract. “Strikingly, a significant number of individuals who abuse alcohol also use Cannabis, which has seen increased legalization globally. While cannabis has demonstrated anti-inflammatory properties, its combined use with alcohol and the development of liver disease remains unclear.”

AVEO Oncology’s Tivozanib Shows Positive Effect In Early-Stage Liver Cancer Study
19 January 2018
AVEO Oncology (AVEO +5.4%) is up on 30% higher volume in response to positive results from the Phase 1b portion of a Phase 1b/2 clinical trial assessing lead drug FOTIVDA (tivozanib) in patients with advanced unresectable Hepatocellular Carcinoma (HCC).

Invitrocue’s Onco-PDO Technology Grows Liver Cancer Outside Of Body
17 January 2018
Invitrocue has again validated its Onco-PDO technology by successfully growing liver cancer outside the human body, opening the door for liver cancer sufferers to receive more personalized drug treatment plans. Using Onco-PDO technology, Invitrocue researchers have been able to culture a variety of patient-derived cancer cells in the laboratory. The cultures or organoids can then be tested against a panel of drugs to facilitate personalized drug treatments in patients and improve outcomes.

Exelixis, Ipsen Report Positive Results On Lead Cancer Drug
17 January 2018
Exelixis, Inc. and Ipsen announced positive detailed results from the pivotal phase III CELESTIAL study of Cabometyx (cabozantinib) demonstrating significant overall survival benefit in patients with previously treated advanced Hepatocellular Carcinoma (HCC).

Bayer To Highlight New Research At ASCO GI 2018 Cancer Symposium
17 January 2018
Bayer announced today that new data from the continued research on Stivarga® (regorafenib) and Nexavar® (sorafenib) in advanced liver cancer will be presented at the 2018 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancer Symposium. The Bayer data include analyses from the RESORCE trial in Hepatocellular Carcinoma (HCC) in addition to the LiverT study in HCC.

Minimally Invasive Liver Resection Reduces Blood Loss, Complications
11 January 2018
Minimally invasive liver resection may be effective for patients with impaired liver function, as results from a recently published study showed that the procedure reduced blood loss and had lower complication rates that led to shorter hospital stays compared with open liver resection. Noda and colleagues retrospectively reviewed the data of 99 patients who underwent hepatectomy for Hepatocellular Carcinoma (n = 96) or combined HCC and cholangiocarcinoma (n = 3).

Married Status May Improve Survival Outcomes In Hepatocellular Carcinoma
5 January 2018
According to a study published in Cancer Management and Research, being married — which may be influenced by race/ethnicity and gender — improved survival outcomes among patients with Hepatocellular Carcinoma (HCC).

First Patient Dosed In Phase 3 Trial Of Beigene’s Therapy Candidate For Advanced Liver Cancer
4 January 2018
Investigators have dosed the first patient in a global Phase 3 trial evaluating the PD-1 inhibitor tislelizumab (BGB-A317) as a first-line therapy for advanced Hepatocellular Carcinoma (HCC) — the most common form of liver cancer — announced BeiGene, the company developing the investigational drug. The trial’s primary goal is to determine if tislelizumab is superior to the current standard of care at improving patient survival. It is part of a collaboration between BeiGene and Celgene, which aims to develop this anti-PD-1 antibody for the treatment of solid tumors.

Netscientific Investee Gets Good Results From Liver Cancer Diagnostic
4 January 2018
In a blind evaluation of 149 Hepatocellular Carcinoma positive patients and control samples, Glycotest’s panel achieved an area under the curve of 0.97 and exhibited 93% sensitivity at 92% specificity, which NetScientific said indicates a high predictability on a statistical basis as to whether liver cancer is present in patients or not.

Beigene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab In Patients With Hepatocellular Carcinoma
2 January 2018
BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that in December 2017 the first patient was dosed in a global Phase 3 clinical trial of tislelizumab, an investigational anti-PD-1 antibody, in patients with previously untreated advanced Hepatocellular Carcinoma (HCC or liver cancer). Along with two pivotal Phase 2 trials in China in relapsed/refractory classical Hodgkin lymphoma and urothelial cancer, and a global Phase 3 trial in patients with non-small cell lung cancer, tislelizumab is now being evaluated in pivotal trials in four distinct indications.

Dr. Abou-Alfa On Checkpoint Inhibitors In Liver Cancer
2 January 2018
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses checkpoint inhibitors in liver cancer. There is a place for checkpoint inhibitors in liver cancer, says Ghassan, but currently he chooses tyrosine kinase inhibitor (TKI) therapy. Upcoming data with checkpoint inhibitors will read out soon and will affect sequencing, he adds.

For past liver cancer news, please visit our Liver Cancer News Archives.

Scroll Up